Ketamine for Suicidality in Bipolar Depression

Randomised, double-blind, parallel-group study (n=16) comparing a single IV infusion of ketamine 0.5 mg/kg with midazolam 0.02 mg/kg for rapid reduction of suicidal ideation in bipolar depression.

Participants require voluntary inpatient admission to NYSPI for the infusion phase; follow-up includes weekly research interviews for 6 weeks; non-responders to midazolam may be offered an open ketamine infusion.